Global Pruritus therapeutics market is expected to reach USD 13.83 billion by 2022, growing at a CAGR of 4.8% between 2016 and 2022
Sarasota, FL -- (SBWIRE) -- 03/09/2017 -- Zion Market Research has published a new report titled "Pruritus Therapeutics Market (Antihistamines, Topical Corticosteroids, Opioid Receptor Antagonists, Topical Immunomodulators, Antidepressants, Immunosuppressants, Topical Local Anesthetics, Cannabinoid Receptors and Others): Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021". The global pruritus therapeutics market was valued at USD 9.54 billion in 2014 and is expected to reach USD 13.83 billion by 2022, growing at a CAGR of 4.8% between 2016 and 2022.
Request Free Sample Research Report @ https://www.zionmarketresearch.com/sample/pruritus-therapeutics-market
Pruritus also known as itch can be caused by a number diseases ranging from dermatological conditions including atopic dermatitis, contact dermatitis, mycoses, chickenpox etc. Pruritus is related with systemic and dermatologic causes. A characteristic itching usually establishes the diagnosis of a key dermatologic disorder. Numbers of skin diseases are associated with pruritus; includes cholestatic pruritus, renal pruritus, endocrine pruritus, hematologic pruritus, idiopathic generalized pruritus and pruritus related to malignancy. Renal pruritus can occur in patients with chronic renal failure. Increased levels of ions such as phosphate, magnesium, and calcium are found in the skin of pruritic patients. Severe pruritus leads to scratching that causes secondary skin problems of dryness, excoriation, eczematization, lichenification and infection. Contact allergy to topical therapies and excessive bathing can lead to pruritus.
Skin disease is the fourth leading cause of nonfatal disease burden. Skin diseases include eczema, psoriasis, acne vulgaris, pruritus, alopecia areata, decubitus ulcer, urticaria, scabies, fungal skin diseases, impetigo, abscess, and other bacterial skin diseases, cellulitis, viral warts, molluscum contagiosum, and non-melanoma skin cancer. Among these types, fungal skin diseases and pruritus were in the top 10 most prevalent diseases worldwide in 2010. Thus pruritus therapeutics market is growing with rising prevalence of skin diseases. Moreover, patent expiration of dermatitis drugs and the introduction of new products are also responsible for the growth of pruritus therapeutics market. However, lack of awareness about pruritus may hamper the growth of pruritus therapeutics market. Nonetheless, untapped market and an increasing number of patent expiry of pruritus drugs may generate new opportunity in the forecast period.
Inquire more about this report @ https://www.zionmarketresearch.com/inquiry/pruritus-therapeutics-market
Based on therapeutic, the market of pruritus therapeutics has been segmented into antihistamines, topical corticosteroids, opioid receptor antagonists, topical immunomodulators, antidepressants, immunosuppressants, topical local anesthetics, cannabinoid receptors and others. Topical corticosteroids segment was valued at USD 1.93 billion in 2014 and is expected to reach USD 2.74 billion by the end of 2022 and in the forecast period, it is expected to grow at around CAGR of 4.6% between 2016 and 2022. Antihistamines segment is a second largest segment with more than 17% market share.
Based on region, the market of pruritus therapeutics has been segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America dominated the market with more than 40% market share and it is expected to grow at around CAGR of 5.0 % in coming years. Europe is the second largest segment in pruritus therapeutics market and is expected to show significant growth in the forecast period as a result of increasing prevalence of skin diseases. Asia-Pacific is projected to witness the fastest growth in the near future and this is due to increase awareness and the government support towards healthcare infrastructure.
Key players operating in the global pruritus therapeutics market include Allergan Inc., Amgen Inc., Astellas Pharma Inc., CARA Therapeutics, Novartis AG, and Teva Pharmaceutical Industries Ltd., Ajanta Pharma ltd, Abbot Lab, GSK and Galderma.
Browse detail report with in-depth TOC @ https://www.zionmarketresearch.com/report/pruritus-therapeutics-market
This report segments the global pruritus therapeutics market as follows:
Global Pruritus Therapeutics Market: Therapeutic Analysis
Opioid Receptor Antagonists
Topical Local Anesthetics
Global Pruritus Therapeutics Market: Regional Segment Analysis
The Middle East and Africa
Request a customized copy of report @ https://www.zionmarketresearch.com/custom/531